Lipoatrophy of the face in HIV seropositives are not susceptible to satisfactory correction by using single cosmetic surgery.

The limitation of the available filler products to augment and to correct the facial defects in facial lipoatrophy is mainly inherent in the amount of substance that can be implanted for the correction of lipoatrophy. Using Bio-Alcamid, which is an injectable, biocompatible, nontoxic, nonallergenic soft tissue filler designed to correct tissue deficits of various volume by intratissue administration, 9 nonrelated HIV seropositive patients with facial lipoatrophy (7 males and 2 females, age 43 ± 6 years) underwent cheek augmentation. From 7 ml to 16 ml of substance was injected each on both cheeks per application up to a maximum total of 25 ml. with a mean amount of 12 ml ± 4 ml. The median follow up time was 2 years. The results revealed that the corrections have remained essentially unchanged throughout the period of follow up. Bio-Alcamid maintained the form and blend with the surrounding tissues.

The surgical outcome was evaluated according to the analysis of photographs obtained before and after surgery, the analysis of pre- and postoperative measurements, and patients’ self-judgment.

The level of satisfaction was significantly high: in 63 % of the cases, the result was judged to be excellent and in 32%, good. Only in 5% of the cases the result was considered poor.

The present study strongly suggests that Bio-Alcamid is suitable for the correction of remarkable defects of facial atrophy, otherwise treatable only by surgery with myofascial free flaps. In addition, it permits a simplification of facial reconstruction and rejuvenation.

Key Words: Cheek augmentation, soft filler, endoprosthesis, Bio-Alcamid, facial rejuvenation, rhytidectomy

Facial lipoatrophy (LA) is characterized by fat loss and redistribution. Facial volume loss is the most obvious outward sign of LA because it alters the facial contours in the cheeks, temples, and orbits. It is most commonly seen in patients with HIV on highly active antiretroviral therapy (HAART), which was introduced in the mid-1990s for the management of HIV, and is currently considered the mainstay therapy for HIV-infected patients.

However, the etiology of LA is likely multifactorial as underlying patient conditions, including duration and severity of HIV and increasing age, have also been found to contribute to its occurrence. The volume loss of LA can be very dramatic with some patients exhibiting no signs of facial fat. As a result, many HIV-infected patients with associated LA suffer from psychological and lifestyle effects. The psychological impact may be severe. Thus, increases in facial volume and improvement in morphology is anticipated to reduce anxiety caused by LA in HIV-infected patients, and improve quality of life.

Treatment approaches may be divided into three categories: 1) surgically-placed alloplastic, autologous, or synthetic implants; 2) injection of temporary fillers; or 3) injection of permanent fillers. Several facial fillers have gained popularity as a means to restore the facial contour. Most are expensive, require multiple visits, and can produce scars. Temporary fillers require ongoing reapplication and permanent fillers may sag if lipoatrophy progresses and can lead to mismatching the host tissue texture.
stable, volume-filling material that is easy to use and remains in place over time and most importantly, is compatible with the host tissue. The latter request is important since it influences the ability of the filler to co-exist with the surrounding tissue, without stimulating the immune system or causing persistent inflammatory reactions, eventually leading to fibrosis.

The limitation of the available products is mainly inherent in the amount of substance that can be implanted for the correction of lipoatrophy. Interest in such compounds have led companies to venture ever further in the search for permanent substance that could replace soft tissue deficits perfectly and definitely, potentially via a simple injection.

Among these fillers is a product called Bio-Alcamid R (Polymekon, Italy). It belongs to the group of hydorgels. Bio-Alcamid is an injectable non biodegradable hydrophobic cross-linked network of branched biopolymeric fluid with a reticulated structure derived from acrylic acid, made up of 96% sterile and apyrogenic water and 4% polyalkyamide gel. It is full of cross-links that remain impenetrable by any cell infiltration, including bacteria, and it is permeable only to ions and O2.

Bio-Alcamid is an injectable soft tissue filler designed to correct tissue deficits of various volume by intratissue administration. It is biocompatible, nontoxic, nonallergenic, easily-injectable, and quickly removable.

After using this method to provide a natural and improved facial contour in nonrelated HIV seropositive patients for more than 3 years, we would like to share our experiences.

**TECHNIQUE**

The treatment was carried out under aseptic conditions, in a sterile field, and with a perioperative antibiotic cover. Bio-Alcamid was injected using 21–23G needle for facial wrinkles and 2–3 mm cannulae for bulkier implants. It was instilled into a single compartment without overfilling the superficial layers of the skin.

From 7 mL to 16 mL of substance was injected each on both cheeks per application up to a maximum total of 25 mL with a mean amount of 12 mL ± 4 mL (Table 1). Injections were performed continuously and evenly from one side to the other in the deepest part of the sunken area at the subcutaneous level only.

**RESULTS**

Nine nonrelated HIV seropositive patients with facial LA (7 males and 2 females, age 43 ± 6 years, one of them has undergone a conventional face lift years before) underwent cheek augmentation. All patients underwent a thorough, individualized preoperative evaluation to establish a correct diagnosis, to evaluate asymmetries, to estimate the degree of LA.

The surgical outcome was evaluated according to the analysis of photographs obtained before and after surgery, the analysis of pre- and postoperative measurement, and patients’ self-judgment.

**Patients**

Nine nonrelated HIV seropositive patients with facial LA (7 males and 2 females, age 43 ± 6 years, one of them has undergone a conventional face lift years before) underwent cheek augmentation. All patients underwent a thorough, individualized preoperative evaluation to establish a correct diagnosis, to evaluate asymmetries, to estimate the degree of LA.

The surgical outcome was evaluated according to the analysis of photographs obtained before and after surgery, the analysis of pre- and postoperative measurement, and patients’ self-judgment.

**Table 1. Amounts to be Injected According to Sites**

<table>
<thead>
<tr>
<th>Region</th>
<th>Amounts of Bio-Alcamid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naso-labial-fold</td>
<td>1 to 3 mL</td>
</tr>
<tr>
<td>Cheeks</td>
<td>7 to 25 mL</td>
</tr>
<tr>
<td>Lip line</td>
<td>1 to 2 mL</td>
</tr>
<tr>
<td></td>
<td>2 mL ± 0.6 mL</td>
</tr>
<tr>
<td></td>
<td>12 mL ± 4.3 mL</td>
</tr>
<tr>
<td></td>
<td>1 mL ± 0.4 mL</td>
</tr>
</tbody>
</table>

After using this method to provide a natural and improved facial contour in nonrelated HIV seropositive patients for more than 3 years, we would like to share our experiences.

The median follow up time was 2 years. Immediate healing was archived without complications or adverse reactions.

All patients healed uneventfully without any postoperative problems. The implantation of Bio-Alcamid caused an immediate modest inflammatory reaction in all patients which subsided within 24–36 hours. The edema, typical in postsurgery, slowly diminished, until vanishing after 2–3 days. Patients usually took up their social life again within 2 days. No migration or dislocation of the implants, no granulomas, no allergic response, and no kind of intolerance were observed. From the first control, the implants resulted soft, and the Bio-Alcamid appeared evenly distributed. The corrections have remained essential unchanged throughout the period of follow up. Bio-Alcamid has maintained the form and blend with the surrounding tissues.

The level of satisfaction was significantly high: in 63% of the cases, the result was judged to be excellent and in 32%, good. Only in 5% of the cases it was considered poor.

Tissue felt soft and the implants were uniformly distributed. In the light of the experience gained so far, the long-lasting results seem to be excellent. The
following examples (Figs 1–4) illustrate the indications and results.

**DISCUSSION**

Bio-Alcamid belongs to the group of hydrogels. Hydrogels are a class of polymers very similar to soft tissues for their high water content, the mechanical properties (very low modulus and elasticity), softness, oxygen permeability, and high biocompatibility. Bio-Alcamid can be defined a sort of “endoprosthesis”, suitable for soft tissue augmentation and for the correction of different tissue deficiencies, with a long-term safety and efficiency. It is a substance easy to inject and remove and which allows one to create volume. It does not migrate, and its safety allows it to be suitable filler for the correction of slight and also very serious aesthetic defects of facial lipoatrophy.

Studies obtained by Lotti et al demonstrated that Bio-Alcamid becomes surrounded by a thin (0.02 nm), well-defined, and permanent capsule. They showed that after about 2 months, the activity of the fibroblasts included in the capsule gradually ceases, and thus the development of the capsule itself was blocked. The capsule, therefore, remained about 0.02 nm thick and, not receiving further stimuli, did not undergo further thickening or sclerosis.

Further studies by Lotti et al have suggested a weak inflammatory reaction of cellular tissue surrounding the implant, and a slow and minimal gel resorption due to the infiltrating macrophages. But the macrophages were not responsible for any evident modification in the structure of Bio-Alcamid, and apparently do not cause gel resorption. The presence and number of CD68 macrophages in the upper perivascular dermis, far from gel implant, decreased significantly after four months. These cells are activated and responsible for the production of TNF-alpha. The fact that the TNF-alpha has a variable biological effect on fibroblast proliferation and that high concentrations inhibit growth is in accordance with the scars expression of fibroblasts found in

---

**Fig 1** Preoperative frontal (A) and lateral (B) view of a patient with severe facial lipoatrophy related to antiretroviral therapy.

**Fig 2** Postoperative view 2 years after Bio-Alcamid R injection of the cheeks and NLF. Frontal view (A) and lateral view (B). The corrections have remained essentially unchanged throughout the period of follow up.

**Fig 3** Schematic drawing of a facial lipoatrophy (right side) and the injection of a filler substance (left side); it illustrates on the left side of the face the area to be filled with Bio-Alcamid for correction of severe facial lipoatrophy. Note that the filling material is beneath the orbicularis muscle.
immune-histo-chemical studies done by Lotti et al.\textsuperscript{16} in 2001. The lack of induction of fibroblast activation is also confirmed by focal expression of fibrogenic cytokine TGF-beta and the lack of expression of IL-6, which, as known, induces collagen synthesis by fibroblasts.\textsuperscript{16}

The present study, along with those previously obtained,\textsuperscript{10-12,14-18} strongly suggests that Bio-Alcamid is suitable for the correction of remarkable defects like facial atrophy, otherwise treatable only by surgery with myofascial free flaps.\textsuperscript{18} In addition, it permits a simplification of facial reconstruction and rejuvenation.

**CONCLUSION**

Bio-Alcamid is suitable for soft tissue augmentation and for correction of facial lipoatrophy, with a long term safety and efficiency. The plasticity, the possibility of modeling, and the capacity to maintain the same texture as the tissue in which it is placed could almost lead one to overlook the other properties of this filler; it is permanent, removable, radiotransparent and nonsensitizing.

**REFERENCES**

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

AQ1 = Please provide manufacturer city.
AQ2 = Please provide Figure 4.
AQ3 = Please confirm the placement of citation for reference 18 here.
AQ4 = Please list 3 authors before using “et al”.
AQ5 = Please check if captured correctly.
AQ6 = Please provide volume number.

END OF AUTHOR QUERIES
**Author Reprints**

For **Rapid Ordering** go to: [www.lww.com/periodicals/author-reprints](http://www.lww.com/periodicals/author-reprints)

### Order

**Journal of Craniofacial Surgery**

**Author(s) Name**

**Title of Article**

*Article # *Publication Mo/Yr ______

*Fields may be left blank if order is placed before article number and publication month are assigned.

<table>
<thead>
<tr>
<th>Quantity of Reprints</th>
<th>Reprint Pricing</th>
<th>Shipping</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$5.00 per 100 for orders shipping within the U.S. $20.00 per 100 for orders shipping outside the U.S.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Covers (Optional)</th>
<th>Shipping Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>$108.00 for first 100 copies</td>
<td>$18.00 each add’l 100 copies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reprint Color Cost</th>
<th>Tax</th>
</tr>
</thead>
<tbody>
<tr>
<td>$10.00/100 reprints</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>$____</td>
</tr>
</tbody>
</table>

You may have included color figures in your article. The costs to publish those will be invoiced separately. If your article contains color figures, use Rapid Ordering [www.lww.com/periodicals/author-reprints](http://www.lww.com/periodicals/author-reprints).

### Payment

<table>
<thead>
<tr>
<th>MC</th>
<th>VISA</th>
<th>Discover</th>
<th>American</th>
<th>Express</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Account #: / / Exp. Date

Name

Address Dept/Rm

City State Zip Country

Telephone

Signature

### Ship to

<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

Address Dept/Rm

City State Zip Country

Telephone

For **Rapid Ordering** go to: [www.lww.com/periodicals/author-reprints](http://www.lww.com/periodicals/author-reprints)